259 related articles for article (PubMed ID: 37428789)
1. The current landscape of therapies for hepatocellular carcinoma.
Coffman-D'Annibale K; Xie C; Hrones DM; Ghabra S; Greten TF; Monge C
Carcinogenesis; 2023 Oct; 44(7):537-548. PubMed ID: 37428789
[TBL] [Abstract][Full Text] [Related]
2. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.
Han K; Kim JH
World J Gastroenterol; 2015 Sep; 21(36):10327-35. PubMed ID: 26420959
[TBL] [Abstract][Full Text] [Related]
3. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia.
Han KH; Kudo M; Ye SL; Choi JY; Poon RT; Seong J; Park JW; Ichida T; Chung JW; Chow P; Cheng AL
Oncology; 2011; 81 Suppl 1():158-64. PubMed ID: 22212951
[TBL] [Abstract][Full Text] [Related]
4. Management of hepatocellular in the United States.
Mokdad AA; Hester CA; Singal AG; Yopp AC
Chin Clin Oncol; 2017 Apr; 6(2):21. PubMed ID: 28482674
[TBL] [Abstract][Full Text] [Related]
5. Image-guided percutaneous locoregional therapies for hepatocellular carcinoma.
Chevallier O; Zhao K; Marinelli B; Yarmohammadi H
Chin Clin Oncol; 2023 Apr; 12(2):17. PubMed ID: 37081710
[TBL] [Abstract][Full Text] [Related]
6. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
Trials; 2012 Aug; 13():144. PubMed ID: 22913492
[TBL] [Abstract][Full Text] [Related]
7. Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma.
Xiang X; Zhong JH; Wang YY; You XM; Ma L; Xiang BD; Li LQ
Clin Transl Oncol; 2017 Jul; 19(7):891-897. PubMed ID: 28160206
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic advances for patients with intermediate hepatocellular carcinoma.
Sun JY; Yin T; Zhang XY; Lu XJ
J Cell Physiol; 2019 Aug; 234(8):12116-12121. PubMed ID: 30648254
[TBL] [Abstract][Full Text] [Related]
9. Management of Hepatocellular Carcinoma: Current Status and Future Directions.
Au JS; Frenette CT
Gut Liver; 2015 Jul; 9(4):437-48. PubMed ID: 26087860
[TBL] [Abstract][Full Text] [Related]
10. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Combined Radiofrequency Ablation with Transarterial Chemoembolization in Patients with Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma Ineligible for Curative Treatment.
Kim AR; Park E; Kwon SY; Park SJ; Kim YJ; Yoo BC; Choe WH; Kim JH; Hwang JH; Park SW; Kim YJ; Park HS; Yu MH; Jeon HJ
Korean J Gastroenterol; 2019 Mar; 73(3):167-176. PubMed ID: 31013560
[TBL] [Abstract][Full Text] [Related]
12. Goals and targets for personalized therapy for HCC.
Couri T; Pillai A
Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478
[TBL] [Abstract][Full Text] [Related]
13. Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.
Choi JY
Oncology; 2011; 81 Suppl 1():141-7. PubMed ID: 22212948
[TBL] [Abstract][Full Text] [Related]
14. Conventional Ethiodized Oil Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma: Contemporary Single-Center Review of Clinical Outcomes.
Casadaban LC; Minocha J; Bui JT; Knuttinen MG; Ray CE; Gaba RC
AJR Am J Roentgenol; 2016 Mar; 206(3):645-54. PubMed ID: 26901023
[TBL] [Abstract][Full Text] [Related]
15. Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma.
Yang B; Zheng B; Yang M; Zeng Z; Yang F; Pu J; Li C; Liao Z
Hepatol Int; 2018 Sep; 12(5):417-428. PubMed ID: 30073454
[TBL] [Abstract][Full Text] [Related]
16. Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects.
Torimura T; Iwamoto H
Clin Mol Hepatol; 2021 Apr; 27(2):236-245. PubMed ID: 33317248
[TBL] [Abstract][Full Text] [Related]
17. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
[TBL] [Abstract][Full Text] [Related]
18. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.
Pecorelli A; Lenzi B; Gramenzi A; Garuti F; Farinati F; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Cabibbo G; Felder M; Morisco F; Gasbarrini A; Baroni GS; Foschi FG; Biasini E; Masotto A; Virdone R; Bernardi M; Trevisani F;
Liver Int; 2017 Mar; 37(3):423-433. PubMed ID: 27566596
[TBL] [Abstract][Full Text] [Related]
19. Treatment of hepatocellular carcinoma: beyond international guidelines.
Sangiovanni A; Colombo M
Liver Int; 2016 Jan; 36 Suppl 1():124-9. PubMed ID: 26725909
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
